Physician profile
Lori A Schultz
NPI 1902995087
$7,345.88
in general payments reported to CMS, 2019-2025
23 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,879 · 2022: $1,741 · 2023: $1,642 · 2024: $983 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.87 |
| Education | $310.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,281.94 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $773.25 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $625.87 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $524.53 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $421.21 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $404.05 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $278.81 | 2021-2025 | |
| Pfizer INC. | $186.32 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $179.18 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $106.93 | 2021-2022 | |
| Amgen INC. | $100.96 | 2021-2024 | Otezla |
| Lilly USA, LLC | $68.70 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $67.42 | 2021 | |
| Almirall LLC | $67.36 | 2021-2023 | Klisyri |
| Allergan, INC. | $53.56 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $46.54 | 2023 | |
| Dermavant Sciences, INC. | $36.84 | 2023 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Mayne Pharma Commercial LLC | $28.19 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.92 | 2023 | Spevigo |
| Incyte Corporation | $17.32 | 2022 | |
| Corium, LLC | $12.88 | 2025 | Azstarys |
| Epi Health, LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.